Investing.com - Nuvectis Pharma reported on Tuesday third quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Nuvectis Pharma announced earnings per share of $-0.42 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.26 on revenue of $-90.
Nuvectis Pharma 's are down 41.36% and is trading at $7.11 , still down 66.01% from its 52 week high of $20.92 set on Wednesday, May 18, 2022.
Nuvectis Pharma shares gained 0.85% to trade at $7.11 in intra-day trade the report.
Nuvectis Pharma follows other major Healthcare sector earnings this month
Nuvectis Pharma's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar